

**FORM 7**

**MONTHLY PROGRESS REPORT**

Name of Listed Issuer: **nDatalyze Corp.** (the “Issuer”).

Trading Symbol: **NDAT**

Number of Outstanding Listed Securities: **41,027,425**

Date: **December 01, 2023**

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer’s obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer’s ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

**General Instructions**

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term “Issuer” includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

## Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

**The Issuer continues to receive non-material revenue from liquidation of its extractor inventory and continues the clinical study process for its YMI mental health system.**

2. Provide a general overview and discussion of the activities of management.

**Management continues to focus on the YMI mental health platform and tasks related to the related clinical study.**

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

**No new products are offered or in development.**

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

**None**

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

**The Issuer entered into two Letters of Intent, one with Dr. Dale Stevens of York University, and one with Personalized Prescribing Inc. for provision of DNA data; both are unrelated and both of which are related to the clinical study.**

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

**None**

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

**The Issuer did not acquire or dispose of any material assets during the period.**

8. Describe the acquisition of new customers or loss of customers.

**None**

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

**None**

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

**The Issuer has no employees - all activities are contract-based.**

11. Report on any labour disputes and resolutions of those disputes if applicable.

**No such developments have occurred during the period.**

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

**The Issuer was not a party to any legal proceedings during the period.**

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

**Beyond usual accounts payable, the Issuer has no debt. This said, the Issuer is in a dispute over approximately \$200,000 in fees charged by its former marketing contractor. The Issuer does not believe that this amount is being pursued by the marketing company and the Issuer has re-allocated the whole amount on its financial statements.**

14. Provide details of any securities issued and options or warrants granted.

**The Corporation closed a non-brokered private placement (the "Offering") of units ("Units"). The Offering consisted of 2,315,000 Units for total gross proceeds of \$277,800. Each Unit consisted of one common share and one-half of one common share purchase warrant, with each warrant entitling the holder thereof to acquire one common share at \$0.25 for 18 months from the date of issuance, subject to accelerated expiry provision described in the Corporation's news release dated October 6, 2023. In connection with the Offering, the Corporation paid eligible finders aggregate cash finders fees of approximately \$4,800 and issued 40,000 finders options to purchase common shares of the Corporation at an exercise price of \$0.25 per common share, within 18 months from the closing date of the Offering. The Corporation intends to use the gross proceeds of the sale of the Units to pay eligible finder fees to eligible finders, to advance the Corporation's Clinical Study related to its YMI machine-learning-based mental health clinical decision system and for general working capital purposes.**

15. Provide details of any loans to or by Related Persons.

**None.**

16. Provide details of any changes in directors, officers or committee members.

**None**

17. Discuss any trends that are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

**The mental health crisis continues and this is expected to contribute to the YMI platform's acceptance going forward. There is no guarantee the YMI mental health platform will prove commercially viable.**

## Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer that has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: **December 1, 2023**

**James M. Durward**  
Name of Director or Senior Officer

***“James M. Durward”***  
Signature

**Chief Executive Officer**  
Official Capacity

<i>Issuer Details</i>	<b>For Month End</b>	<b>Date of Report - YY/MM/DD</b>
<b>Name of Issuer</b> nDatalyze Corp.	November 2023	2023/12/01
<b>Issuer Address</b> 1150, 707 – 7 <sup>th</sup> Avenue SW		
<b>City/Province/Postal Code</b> Calgary, Alberta T2P 3H6	<b>Issuer Fax No.</b> N/A	<b>Issuer Telephone No.</b> 403-689-3901
<b>Contact Name</b> James M. Durward	<b>Contact Position</b> CEO	<b>Contact Telephone No.</b> 403-689-3901
<b>Contact Email Address</b> jimd@ndatalyze.com	<b>Web Site Address</b> www.ndatalyze.com	